ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe

 
• By Kevin Grogan

Fresh from raising €16m in a Series A round, Albert Palomer, CEO of Spain's ABAC Therapeutics, has outlined to Scrip the company's pathogen-specific approach to antibiotic research and his fears that biotechs in Europe are being held back by flaws in the continent's 'push' incentives schemes.

Carrot
Are incentives for antibiotic R&D working? • Source: Shutterstock

More from Anti-infective

More from Therapy Areas